Microencapsulation Market 2024 Key Players BASF, Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
microencapsulation market size across these regions is heavily driven by the growing demand for microencapsulated drugs, not to mention, the extensive R&D activities in the healthcare field.
(EMAILWIRE.COM, August 20, 2018 ) A report by Global Market Insights, Inc., claims that Microencapsulation Market is likely to grow at a CAGR of 8% over 2017-2024, with a target revenue estimation of more than USD 14 billion by 2024. It is prudent to mention that companies partaking in this business share have been spending excessively on R&D activities, to bring about certain essential changes in the product deployment and commercialization, that is certain to further impel microencapsulation industry size in the forthcoming years.
The recent Frutarom-AB-Biotics agreement has sent out waves of anticipation in microencapsulation market, given that the deal has been signed by Frutarom to acquire AB Biotics’ iron deficiency ingredient unit, AB-Fortis. Apparently, the Israel-based flavor company plans to encompass AB-Fortis into its established framework of specialty fine ingredients, and tap into its microencapsulation technology to increase the absorbability of iron in tissues, and enable a reduced iron dosage in ingredient extracts, without any side effects or any compromise on the taste factor.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2107
With the acquisition of AB-Fortis, Frutarom has successfully crossed a double benchmark – that of having firmly established its space in microencapsulation industry, while simultaneously having made its tenth acquisition of 2017 so far, the last one being, 210-million-dollar takeover of the Israel ingredients company, Enzymotec.
Furthermore, it is prudent to mention that AB-Fortis’ inclusion within Frutarom’s umbrella may prove to be highly beneficial for the ex-iron-deficiency-ingredient unit of the Spanish biotech company AB-Biotics. Considering the prominence of Frutarom in the growing specialty health ingredients market, it is expected that the company will exploit the full potential of AB-Fortis to mark a precedence in the microencapsulation market as well.
Microencapsulation technology finds extensive applications across a plethora of end-use domains, though the pharmaceutical sphere, by far, remains one of the most lucrative sectors. In 2016 alone, the pharma domain accounted for a revenue of USD 4 billion from the overall microencapsulation industry share, driven by the deployment of this technology for improving the process and effectiveness of drug delivery and camouflage the bitter taste of medicines.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2107
Also, this sector has achieved commendable prominence in the developed regions of the globe, thereby providing an impetus to the overall microencapsulation market size. As per statistics, the pharma sector in North America is in exceedingly good shape, driven by the contribution of the United States, which is touted to be the most important pharmaceutical market is the world. In conjunction with Mexico and Canada in fact, it represents the biggest continental pharmaceutical business globally, which is evidence enough to claim that North America is one of most remunerative grounds for microencapsulation industry.
Estimates state that the U.S. alone accounts for more than 45% of the overall pharma business – in 2016, its contribution toward the global pharma sphere has been touted to be around USD 446 billion. Given the robust expansion of this sector in the U.S., it has been forecast that U.S. microencapsulation market share is likely to accumulate substantial revenue in the ensuing years.
The recent Frutarom-AB-Biotics agreement has sent out waves of anticipation in microencapsulation market, given that the deal has been signed by Frutarom to acquire AB Biotics’ iron deficiency ingredient unit, AB-Fortis. Apparently, the Israel-based flavor company plans to encompass AB-Fortis into its established framework of specialty fine ingredients, and tap into its microencapsulation technology to increase the absorbability of iron in tissues, and enable a reduced iron dosage in ingredient extracts, without any side effects or any compromise on the taste factor.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2107
With the acquisition of AB-Fortis, Frutarom has successfully crossed a double benchmark – that of having firmly established its space in microencapsulation industry, while simultaneously having made its tenth acquisition of 2017 so far, the last one being, 210-million-dollar takeover of the Israel ingredients company, Enzymotec.
Furthermore, it is prudent to mention that AB-Fortis’ inclusion within Frutarom’s umbrella may prove to be highly beneficial for the ex-iron-deficiency-ingredient unit of the Spanish biotech company AB-Biotics. Considering the prominence of Frutarom in the growing specialty health ingredients market, it is expected that the company will exploit the full potential of AB-Fortis to mark a precedence in the microencapsulation market as well.
Microencapsulation technology finds extensive applications across a plethora of end-use domains, though the pharmaceutical sphere, by far, remains one of the most lucrative sectors. In 2016 alone, the pharma domain accounted for a revenue of USD 4 billion from the overall microencapsulation industry share, driven by the deployment of this technology for improving the process and effectiveness of drug delivery and camouflage the bitter taste of medicines.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2107
Also, this sector has achieved commendable prominence in the developed regions of the globe, thereby providing an impetus to the overall microencapsulation market size. As per statistics, the pharma sector in North America is in exceedingly good shape, driven by the contribution of the United States, which is touted to be the most important pharmaceutical market is the world. In conjunction with Mexico and Canada in fact, it represents the biggest continental pharmaceutical business globally, which is evidence enough to claim that North America is one of most remunerative grounds for microencapsulation industry.
Estimates state that the U.S. alone accounts for more than 45% of the overall pharma business – in 2016, its contribution toward the global pharma sphere has been touted to be around USD 446 billion. Given the robust expansion of this sector in the U.S., it has been forecast that U.S. microencapsulation market share is likely to accumulate substantial revenue in the ensuing years.
Contact Information:
Global Market Insights, Inc.
Arun Hegde
Tel: 1-888-689-0688
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Global Market Insights, Inc.
Arun Hegde
Tel: 1-888-689-0688
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results